280 related articles for article (PubMed ID: 28111425)
1. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
[TBL] [Abstract][Full Text] [Related]
2. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
3. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
[
